To determine whether stress-evoked release of endogenous opioids might account for hypoalgesia in major depressive disorder (MDD), the µ-opioid antagonist naltrexone (50 mg) or placebo was administered double-blind to 24 participants with MDD and to 31 non-depressed controls. Eighty minutes later participants completed a painful foot cold pressor test and, after a 5-minute interval, began a 25-minute arithmetic task interspersed with painful electric shocks. Ten minutes later participants completed a second cold pressor test. Negative affect was greater in participants with MDD than in non-depressed controls throughout the experiment, and increased significantly in both groups during mental arithmetic. Before the math task, naltrexone unmasked direct linear relationships between severity of depression, negative affect while resting quietly, and cold-induced pain in participants with MDD. In contrast, facilitatory effects of naltrexone on cold-and shock-induced pain were greatest in controls with the lowest depression scores. Naltrexone strengthened the relationship between negative affect and shock-induced pain during the math task, particularly in the depressed group, and heightened anxiety in both groups toward the end of the task. Thus, µ-opioid activity apparently masked a positive association between negative affect and pain in the most distressed participants. These findings suggest that psychological distress inhibits pain via stress-evoked release of opioid peptides in severe cases of MDD. In addition, tonic endogenous opioid neurotransmission could inhibit depressive symptoms and pain in people with low depression scores.
comparison to the general adult population, controls reported lower than average levels of state anxiety (women 39 th mean percentile rank; men 44 th mean percentile rank) and trait anxiety (women 42 nd mean percentile rank; men 43 rd mean percentile rank), and levels of depression and stress were within the normal range. Conversely, depressed participants reported moderate to severe symptoms of state and trait anxiety, matching levels in the top 2-5% of the general population [44] . All participants reported that they were in good health.
Exclusion criteria included psychotic disorders, alcohol and/or other substance use disorders, benzodiazepines, DSM-IV Axis II disorders, cigarette smoking, chronic pain conditions or headache (all identified during the structured clinical telephone interview). In addition, respondents currently taking hypericum perforatum (St John's Wort) or antidepressant medication were excluded. Five participants had taken selective serotonin reuptake inhibitors in the past but had ceased taking these drugs five weeks to six months (median four months) before their recruitment into the study. Participants reduced their alcohol intake for one week prior to testing, and refrained from alcoholic or caffeinated beverages for 12 hours before the experiment. They also refrained from food for two hours before the experiment. None of the participants used opiates regularly or had ever taken naltrexone.
Participants provided informed consent for the procedures which were approved by the Murdoch University Human Research Ethics Committee. Two depressed participants withdrew from the experiment during the math task and one control withdrew because of an adverse reaction to naltrexone (vertigo). Participants received $20 for their participation.
Procedures
Design overview. The experiment was carried out in a laboratory maintained at 22
± 2°C. The participants were randomly assigned to either a naltrexone or placebo
condition. An identical capsule containing a 50 mg caplet of naltrexone or a sugar pill was administered double-blind. This dose of naltrexone blocks the subjective and objective effects of intravenous opioid challenge [11, 21] , and would be expected to block effects of endogenous opioid release. When asked after the experiment whether they thought that they had taken naltrexone, participants guessed correctly at a rate no greater than chance. In the depressed group, four men and six women took naltrexone, and another seven men and seven women took the placebo. In the control group, six men and eight women took naltrexone, and another eight men and nine women took the placebo. Eighty minutes later, after the naltrexone had been absorbed [21] , participants completed a cold pressor test and, after a 5-minute interval, began a 25-minute arithmetic task. Participants completed a second cold pressor test ten minutes after the arithmetic task. Naltrexone has a half-life of approximately four hours [11] .
Dependent variables. Prior to drug absorption, an hour later and again after the math task, participants rated anxiety, discouragement, anger and filler items (confusion, sluggishness and liveliness) on separate 100 mm visual analogue scales ranging from "not at all" to "extremely". The participants were instructed to rate how they felt right now. Subjects rated their mood using the same scales at intervals of 5-7 minutes during the arithmetic task, starting 1.5 minutes into the task. During the cold pressor test participants rated pain and unpleasantness at 30-second intervals using two 0-10 point verbal rating scales until the pain became intolerable -at which point a final rating was made (0 corresponded to 'no pain' or 'not unpleasant at all' and 10 to 'pain as bad as it could get' or 'as unpleasant as it could get'). In addition, the intensity and unpleasantness of seven painful electric shocks administered during the math task were rated on 100 mm visual analogue scales ranging from "no pain" or "not unpleasant at all" to "pain as bad as it could get" or "as unpleasant as it could get".
Cold pressor test. Participants immersed their non-dominant foot to the top of the lateral malleolus in 37°C water for three minutes to standardise foot temperature, then placed their foot in 2°C ice-water for as long as they could tolerate or until four minutes had elapsed. A small aquarium pump circulated the ice-water to prevent pockets of warm water developing around the foot.
Math task. Addition and subtraction items varied across five levels of difficulty, and the difficulty of the problems was adjusted automatically to ensure a 75% failure rate across the 25 minutes of the task [20] . At the outset of the task subjects were told that the number of shocks that they would receive would depend on their performance. However, no such contingency existed and all participants received an identical number of shocks at similar stages throughout the task. Each math question appeared in yellow 2 cm high numbers in the middle of a black computer screen. To increase the difficulty of the task, subjects used their non-dominant hand to type in their answers using the row of numbers at the top of a computer keyboard (and not the number-pad). Once a problem was Electric shocks. Seven 15 mA shocks of 25 milliseconds duration were delivered at irregular intervals throughout the math task to prevent subjects from anticipating their occurrence. Each pulse was delivered by an SD9 Grass Square Pulse stimulator and constant current unit via 1 cm 2 silver/silver chloride surface electrodes filled with watersoluble electrode gel and attached 2 cm apart over the right lateral sural nerve behind the lateral malleolus. The skin was slightly abraded with a pumice stone and degreased with an alcohol swab to reduce skin impedance below 5 KΩ. The math task was suspended after each shock whilst subjects gave pain intensity and unpleasantness ratings.
Data analysis
Mood ratings. Changes in anxiety, discouragement and anger over the course of the experiment were investigated in Group (depressed, control) x Drug (natrexone, placebo) x Time (before drug administration, 60 minutes after drug administration, five times during the math task, and shortly after the math task) analyses of variance. The multivariate solution was employed for repeated measures factors with more than two levels. Significant effects that included Time were investigated in planned contrasts between consecutive time points.
Cold-induced pain. Tolerance scores derived from the duration of foot immersion were log-transformed to reduce the distribution skew created by participants who tolerated the cold pressor test for the entire four-minute period. These log-transformed scores, and mean ratings of the intensity and unpleasantness of pain, were investigated in The criterion of statistical significance was p<0.05. Data are reported as the mean + standard error.
Results

Mood ratings
As shown in Figure (difference between pre-math anxiety and first measure during math, p<0.001) and remained high until after the task had finished (difference between the final measure during math and the post-math measure, p<0.05 for discouragement and p<0.01 for anger). Naltrexone did not influence ratings of discouragement or anger in depressed or non-depressed participants.
Cold-induced pain
Both before and after the math task, approximately 40% of participants tolerated the cold pressor test for the entire four-minute period. These participants were spread fairly evenly across the naltrexone and placebo conditions in the depressed and control groups ( Table 2 ). The cold pressor test was rated as moderately to intensely painful and unpleasant: intensity ratings averaged 7.5 + 0.3 and unpleasantness ratings averaged 7.8 + 0.3 on 0-10 scales. In the group as a whole, neither pain tolerance nor pain ratings differed between the naltrexone and placebo conditions, or between depressed participants and controls, before or after the math task (none of the F ratios that included these effects were statistically significant).
In depressed participants who took naltrexone, depression severity and negative affect before the first cold pressor test was greatest in those who subsequently reported most cold-induced pain (Table 3) . However, this relationship moved in the opposite direction in depressed patients who took the placebo. Hierarchical multiple linear regression analyses confirmed that naltrexone reversed the relationship between negative affect/depression severity and pain in depressed participants during the first cold pressor test (Table 3) . Naltrexone also reversed the association between depression severity and pain unpleasantness after the math task (Table 4 ), but did not alter the relationship between pain and anxiety, discouragement or anger.
Naltrexone did not influence the association between negative affect and pain in controls, either before or after the math task (Tables 3 and 4) . Curiously, however, naltrexone unmasked a negative association between pain ratings and depression severity scores in controls (Tables 3 and 4) .
Shock-induced pain
Electric shocks administered during the math task were rated as moderately painful. Neither ratings of pain intensity nor unpleasantness differed significantly between depressed participants and controls, or between the naltrexone and placebo conditions.
In the naltrexone condition, the intensity and unpleasantness of shock-induced pain was greatest in subjects who reported most negative affect (Table 5) . In depressed participants, the relationship between pain ratings and negative affect was stronger in the naltrexone condition than the placebo condition (Table 5) . Pain ratings were unrelated to depression severity scores in the MDD group, but were negatively associated with depression severity scores in controls administered naltrexone (Table 5) .
Discussion
The main finding of this study was that the µ-opioid receptor antagonist naltrexone strengthened the relationship between negative affect and pain, particularly in the MDD group. This finding suggests that psychological stress triggered the release of endogenous opioid peptides in the most distressed participants, and that µ-opioid activity masked a direct linear relationship between negative affect and pain.
Stress-induced analgesia
Opioid analgesia has been identified in a diverse range of animal models, characterized by lack of control over aversive stimuli such as cold-water immersion, electric shocks, and centrifugal rotation [1, 41] . In human research, µ-opioid receptor blockade antagonized stress-induced analgesia evoked by noxious electric shocks [47, 48] , immersion of a limb in ice-water [28, 40] , the perception of failure on a difficult cognitive task [2, 3, 20] , a combat video shown to Vietnam veterans with post-traumatic stress disorder [38] , and a first-time parachute jump [27] . Effects of µ-opioid receptor blockade on experimental pain are more variable [16, 23, 40] , possibly because of individual differences in sensitivity to or release of opioid peptides. For example, naloxone augments shock-induced pain and cortical evoked potentials in pain-tolerant people, but inhibits pain and cortical evoked potentials in pain-sensitive people [10] . We recently reported that µ-opioid receptor blockade facilitated pain induced by repeated immersions of a hand in ice-water in pain-tolerant subjects, but had no effect on pain induced by the first, less stressful, immersion [40] . In the present study, naltrexone failed to augment pain induced by electric shocks or single ice-water immersions in the group as a whole. Thus, psychological stress may trigger endogenous opioid release more readily than transient painful stimulation.
We previously investigated the effect of naltrexone on cold-induced pain in nondepressed people before and after stressful mental arithmetic [20] . To heighten negative affect, participants received noxious electric shocks at irregular intervals throughout the math task. Within the naltrexone condition, cold-induced pain and unpleasantness increased after the math task in line with ratings of discouragement. This relationship was absent in the placebo condition, implying that opioid release inhibited cold-induced pain in the most discouraged cases. In the present study, a similar protocol was employed to investigate effects of MDD on stress-induced opioid analgesia. In contrast to our previous report [20] , naltrexone unmasked a positive association between negative affect and coldinduced pain before the math task in depressed participants; moreover, in the naltrexone condition, both cold-induced pain and unpleasantness increased in line with depression severity. These relationships were absent in the placebo condition, implying that psychological distress mobilized the opioid system in MDD. Thus, our findings suggest that chronic stress-induced activation of the opioid system inhibited cold-induced pain in severely depressed participants. In emotionally-neutral states, the bioavailability of µ-opioid receptors in the posterior thalamus is lower in women with MDD than in nondepressed controls, consistent with chronic over-activity of the opioid system in MDD [30] . Bioavailability of µ-opioid receptors decreases in this part of the brain during painful stimulation [7, 50] , presumably due to pain-induced release of endogenous opioids.
During stressful mental arithmetic, naltrexone strengthened an association between negative affect and shock-induced pain, particularly in the MDD group. Opioid activity increases in the subamygdalar-left inferior temporal cortex of depressed patients during sustained sadness, and increases in the anterior cingulate region of patients who fail to respond to antidepressant medication [30] . Thus, the µ-opioid system may be overactive in severely affected MDD patients, not only at rest but also during emotional challenges.
After the math task, naltrexone strengthened an association between pain unpleasantness and severity of depression in the MDD group, suggesting that opioid analgesia was greatest in the most severely depressed cases. Surprisingly, however, naltrexone-hyperalgesia was unrelated to the intensity of negative affect. The reason for this discrepancy is unclear, but may be due to the development of non-opioid analgesia during stressful mental arithmetic. Non-opioid analgesic mechanisms appear to be active during stressful experiences until the outcome is no longer easily controlled; this loss of control then augments endogenous µ-opioid neurotransmission [2, 29] .
Curiously, naltrexone-hyperalgesia was greatest in controls with the lowest depression severity scores (contrary to participants with MDD). Opioid activity decreases in the rostral anterior cingulate region of non-depressed controls during sustained sadness, in association with heightened negative affect [30] . Thus, in the absence of depression, sadness may be associated with a reduction in normal, background opioid release in a region of the brain that regulates affective responses. The present findings suggest that naltrexone blocked an analgesic effect of tonic opioid release in nondepressed controls with few or no depressive symptoms. Importantly, naltrexone had little influence on the mood-pain relationship in this group, implying that heightened tonic µ-opioid neurotransmission was associated more closely with lack of depressive symptoms than with negative affect.
Effect of naltrexone on mood
Negative affect was greater in depressed than non-depressed participants throughout the study, as was the unpleasantness of shock-induced pain. Although increments in negative affect were similar in both groups during the math task, naltrexone blocked decreases in anxiety toward the end of the task. Thus, stress-induced opioid release apparently suppressed anxiety both in MDD participants and non-depressed controls. Functional neuroimaging studies suggest that the endogenous opioid system has an anxiolytic role in regions of the temporal lobe that project to the amygdala [35] , and suppresses affective states such as sadness [30, 51] .
Negative affect during stressful mental arithmetic increased in line with the intensity and unpleasantness of shock-induced pain, particularly in the naltrexone condition. The positive association between negative affect and pain could reflect several mechanisms, including hypervigilance to pain, muscular reactivity, autonomic arousal, or misattribution of arousal in distressed participants [26] . Alternatively, the pain provoked by the electric shocks may have enhanced negative affect. Animal studies have implicated activation of the limbic system, a deficit in central serotonergic neurotransmission, dysfunction of the hypothalamic-pituitary-adrenal axis, and hypofunction of supraspinal µ-opioid receptors in various models of stress-induced hyperalgesia [25] . Whatever the mechanism, the present findings indicate that endogenous opioids masked the relationship between negative affect and pain, particularly in the MDD group.
Limitations
The rigorous inclusion and exclusion criteria used to select MDD participants and controls places limits on how far the present findings might generalize to their respective populations. Many potential recruits with MDD were excluded because they took drugs that might affect µ-opioid neurotransmission (antidepressants, nicotine, psychotropic agents or pain medication). Controls had to be free of psychiatric illness, both personally and within their immediate family. The use of these selection criteria may account for discrepancies between the present findings and those reported previously. For example,
we previously found evidence of opioid analgesia in discouraged participants after stressful mental arithmetic [20] . In contrast, opioid analgesia after the math task was unrelated to discouragement in the present study, perhaps due to a restricted range of affect within homogenous groups of participants.
In a second important discrepancy, naltrexone enhanced anxiety during the math task in the present study. The present sample of participants was recruited from the community, and might have felt more threatened by task demands (thereby activating the opioid system more strongly to counteract anxiety) than the previous university-based sample [20] .
We asked participants to rate discouragement rather than sadness because loss of control (akin to a sense of helplessness or hopelessness) appears to be important both in depression [24] and in stress-induced opioid analgesia [2, 3] . In retrospect, however, it would have been interesting to measure sadness in addition to discouragement because melancholia is a major feature of depression.
Finally, opioid analgesia was greater in women than men in our previous study [20] , possibly because women became more discouraged than men during the math task.
The sample recruited for the present study was not large enough to investigate sex differences in opioid analgesia within the MDD population. However, sex differences may be important because women are more sensitive to pain than men [17, 46] due, in part, to modulatory effects of oestrogen on subcortical opioid neurotransmission [43] .
Conclusions
Lautenbacher et al. [33] reported that µ-opioid receptor blockade had no consistent effect on heat pain thresholds in depressed patients. Similarly, in the present study, naltrexone had no consistent effect on pain intensity in the MDD group as a whole, either before, during or after psychological stress. Nevertheless, naltrexone strengthened the relationship between negative affect and cold-and shock-induced pain, particularly in the MDD group, consistent with heightened µ-opioid neurotransmission and opioid analgesia in the most distressed cases. These findings support the view that the opioid system, which forms an interface between physical and emotional stress regulation [39] , is chronically over-active in the most severe cases of MDD [30] . Further studies are required to determine whether this over-activity promotes opioid tolerance, a factor implicated in the development of chronic pain [9] .
Our findings also suggest that high tonic µ-opioid neurotransmission inhibited pain in controls with few or no symptoms of depression. If so, high tonic levels of opioid activity might decrease vulnerability to depressive symptomatology. Note: the proportion of participants who tolerated the cold pressor test for the full four minutes did not differ significantly between the placebo or naltrexone conditions in depressed participants or controls, either before or after the math task. ^ The Drug x Depression Severity/negative affect interaction in hierarchical multiple linear regression analyses, which tests whether correlations differ between the placebo and naltrexone conditions. 
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